< Back to previous page
Researcher
Michel Koole
- Disciplines:Medical imaging and therapy, Medicinal products
Affiliations
- Nuclear Medicine & Molecular Imaging (Division)
Member
From1 Jan 2007 → Today
Projects
1 - 10 of 21
- A whole-body physiologically based pharmacokinetic model for personalized 161Tb-PRRTFrom1 Oct 2023 → TodayFunding: SCK (Study Centre Nuclear Energy)
- '213Bi-188Ready' Improved Theranostics with Bismuth-213 and Rhenium-188From1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Fast quantitative SPECT imaging for patient specific dosimetry to facilitate personalized 177Lu-PSMA treatmentFrom18 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Metrology for emerging targeted alpha therapiesFrom1 Sep 2023 → TodayFunding: H2020 - European Institute of Innovation and Technology
- IMAGINATION : IMAGing bIomarkers for diagNosis, therAnosTIcs and drug develOpmeNtFrom1 Oct 2022 → TodayFunding: IOF - mandates
- Low dose, high resolution Ga-68 PET imaging for oncological indicationsFrom25 May 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Innovative concepts for PET-MR imaging of brain function and brain-gut interactionsFrom14 Jan 2022 → TodayFunding: BOF - doctoral mandates
- Modelling of tumor control probability in preclinical targeted radionuclide therapyFrom1 Oct 2021 → TodayFunding: SCK (Study Centre Nuclear Energy)
- 18F-PSMA-1007 PET/MR imaging, quantification and radiomics in the primary staging of prostate cancer and response prediction after neoadjuvant hormonal therapyFrom1 Aug 2021 → TodayFunding: FWO Strategic Basic Research Grant
- "Dosimetry aspects of recoiling daughter nuclides of 225-Actinium in Targeted Alpha Therapy"From8 Nov 2019 → 15 Jul 2022Funding: SCK (Study Centre Nuclear Energy)
Publications
31 - 40 of 186
- A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT)(2022)
Authors: Kaat Spoormans, Michel Koole
- A visual ensemble approach using deep convolutional neural networks for 3D segmentation of breast tumors on dynamic contrast enhanced MRI(2022)
Authors: Masoomeh Rahimpour, Michel Koole
- The EARL Quantitative(177)Lu-SPECT-CT accreditation programme(2022)
Authors: Michel Koole
Pages: S187 - S187 - Simplified Semi-Quantification of [F-18]PSMA-1007 Uptake in Treatment-Naive Primary Prostate Cancer(2022)
Authors: Michel Koole, Wouter Everaerts, Steven Joniau, Christophe Deroose, Karolien Goffin
Pages: S505 - S506 - Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals(2022)
Authors: Michel Koole
- Impact of meningeal uptake and partial volume correction techniques on [18F]MK-6240 binding in aMCI patients and healthy controls(2022)
Authors: Laura Michiels, Greet Vanderlinden, Mathieu Vandenbulcke, Robin Lemmens, Koen Van Laere, Michel Koole
Pages: 1236 - 1246 - Cannabinoid receptor availability modulates the magnitude of dopamine release in vivo in the human reward system: A preliminary multitracer positron emission tomography study(2022)
Authors: Jenny Ceccarini, Michel Koole
- The Effect of Aging on Brain Glucose Metabolic Connectivity Revealed by [18F]FDG PET-MR and Individual Brain Networks(2022)
Authors: Stefan Sunaert, Koen Van Laere, Michel Koole
- Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer(2022)
Authors: Nathalie Mertens, Michel Koole, Wouter Everaerts, Steven Joniau, Raymond Oyen, Koen Van Laere, Karolien Goffin
Pages: 901 - 911 - The PET tracer [11C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer's disease(2022)
Authors: Guy Bormans, Michel Koole, Koen Van Laere